| Dimopoulos, Meletios A |
| Completed | 3 | 202 | Europe | Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib | University of Ulm, Centre Hospitalier de Lens (Co-Sponsor) | Waldenström's Macroglobulinemia | 11/18 | 04/24 | | |
| Terminated | 3 | 205 | Europe, RoW | Plitidepsin, Dexamethasone, Remdesivir, Favipiravir | PharmaMar | COVID-19 Infection | 03/23 | 03/23 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 177 | Europe, Canada, US, RoW | Belantamab mafodotin | GlaxoSmithKline | Multiple Myeloma | 08/24 | 02/25 | | |
|
DREAMM 5, NCT04126200 / 2019-001138-32: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 2 | 209 | Europe, Canada, US, RoW | Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide | GlaxoSmithKline | Multiple Myeloma | 02/29 | 02/29 | | |
|
|
|
|
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
NCT05573802 / 2022-001942-39: A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1/2 | 36 | Europe | Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone, Nirogacestat | Hellenic Society of Hematology, GlaxoSmithKline | Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease | 10/26 | 10/26 | | |
DREAMM 12, NCT04398745: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function |
|
|
| Recruiting | 1 | 36 | Europe, US, RoW | Belantamab mafodotin, GSK2857916 | GlaxoSmithKline | Multiple Myeloma | 02/25 | 02/25 | | |
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function |
|
|
| Recruiting | 1 | 28 | Europe, US, RoW | Belantamab mafodotin | GlaxoSmithKline | Multiple Myeloma | 11/25 | 11/25 | | |
ROADMAP-MM, NCT03405571: Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias. |
|
|
| Recruiting | N/A | 800 | Europe | No intervention | University of Athens, Pierre and Marie Curie University | Multiple Myeloma, Venous Thromboembolism | 06/20 | 06/22 | | |
NCT04408209: Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection |
|
|
| Completed | N/A | 60 | Europe | Convalescent Plasma | National and Kapodistrian University of Athens, Hellenic Society of Hematology | COVID-19 Infection | 08/23 | 12/23 | | |
| Terpos, Evangelos |
The APOLLO Study, NCT03180736 / 2017-001618-27: Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone |
|
|
| Active, not recruiting | 3 | 304 | Europe, RoW | Daratumumab, Pomalidomide, Dexamethasone | European Myeloma Network, Janssen Research & Development, LLC | Multiple Myeloma | 07/20 | 06/22 | | |
|
|
|
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients |
|
|
| Active, not recruiting | 3 | 117 | Europe, RoW | Ropeginterferon alfa-2b (BESREMi®) | AOP Orphan Pharmaceuticals AG | Essential Thrombocythaemia | 03/28 | 03/28 | | |
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma |
|
|
| Recruiting | 3 | 222 | Europe, US | Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral | Stichting European Myeloma Network, Karyopharm Therapeutics Inc | Multiple Myeloma | 03/26 | 03/29 | | |
|
|
EUMELEIA, NCT06636552: An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L |
|
|
| Recruiting | 2 | 43 | Europe | Daratumumab (Subcutaneously) | Hellenic Society of Hematology | Primary Plasma Cell Leukemia | 01/29 | 01/29 | | |
TAURUS, NCT06189833: Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - |
|
|
| Recruiting | 2 | 200 | Europe | Daratumumab, JNJ-54767414, Bortezomib, Velcade, Lenalidomide, Dexamethasone | Stichting European Myeloma Network, Janssen Pharmaceutica | Multiple Myeloma | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 160 | Europe | Iberdomide | Stichting European Myeloma Network, Celgene Corporation, Healt Data Specialists - HeaDS (CRO), EMN Research Italy Impresa Sociale Srl | Multiple Myeloma | 07/23 | 12/27 | | |
| Recruiting | 2 | 50 | Europe | Elranatamab | Stichting European Myeloma Network, Pfizer | Smoldering Multiple Myeloma | 07/27 | 07/31 | | |
EAE116, NCT05147493 / 2021-004895-32: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment |
|
|
| Not yet recruiting | 2 | 51 | Europe | Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, Lenalidomide | Hellenic Society of Hematology, Sanofi | Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases | 12/24 | 02/25 | | |
EAE115, NCT05298683 / 2021-004917-38: A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor |
|
|
| Not yet recruiting | 2 | 108 | Europe | Isatuximab, Pomalidomide, Dexamethasone, Acetaminophen (paracetamol), Ranitidine (or equivalent), Diphenhydramine (or equivalent) | Hellenic Society of Hematology, Sanofi | Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases | 11/25 | 01/26 | | |
NCT04891809: Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM |
|
|
| Recruiting | 2 | 198 | Europe, RoW | Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral | Arbeitsgemeinschaft medikamentoese Tumortherapie, University of Navarra, Medical University of Vienna, Assign Data Management and Biostatistics GmbH, WiSP GmbH, Sanofi | Newly Diagnosed Multiple Myeloma | 12/27 | 12/28 | | |
EAE120, NCT05280275 / 2021-006792-42: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible |
|
|
| Recruiting | 1/2 | 36 | Europe | Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide, Dexamethasone | Hellenic Society of Hematology, GlaxoSmithKline | Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease | 03/26 | 03/26 | | |
NCT05581875 / 2022-001941-19: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory |
|
|
| Not yet recruiting | 1/2 | 48 | NA | Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide, Dexamethasone | Hellenic Society of Hematology, GlaxoSmithKline | Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell | 10/26 | 10/26 | | |
NCT05573802 / 2022-001942-39: A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1/2 | 36 | Europe | Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone, Nirogacestat | Hellenic Society of Hematology, GlaxoSmithKline | Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease | 10/26 | 10/26 | | |
| Active, not recruiting | 1/2 | 66 | Europe | Belantamab mafodotin, Blenrep | Hellenic Society of Hematology, GlaxoSmithKline | Multiple Myeloma | 09/28 | 11/28 | | |
|
NCT04743388: Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System |
|
|
| Recruiting | N/A | 600 | Europe | BNT162b2, Other vaccine against SARS-Cov-2 | National and Kapodistrian University of Athens | COVID-19, Healthy Volunteers, Chronic Disease, Hematological Malignancies, Solid Tumor | 08/22 | 12/22 | | |
| Completed | N/A | 1054 | Europe, RoW | | Stichting European Myeloma Network, Fondazione EMN Italy Onlus | Multiple Myeloma, Covid19, Corona Virus Infection | 08/22 | 03/24 | | |
NCT04408209: Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection |
|
|
| Completed | N/A | 60 | Europe | Convalescent Plasma | National and Kapodistrian University of Athens, Hellenic Society of Hematology | COVID-19 Infection | 08/23 | 12/23 | | |
